High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a)

@article{Franke2019HighRR,
  title={High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a)},
  author={V. Franke and D. Berger and W. Klop and B. van der Hiel and B. A. Van de Wiel and S. ter Meulen and M. Wouters and W. V. van Houdt and A. V. van Akkooi},
  journal={International Journal of Cancer},
  year={2019},
  volume={145}
}
Talimogene laherparepvec (T‐VEC) is a modified herpes simplex virus, type 1 (HSV‐1), which can be administered intralesionally in patients with stage IIIB/C‐IVM1a unresectable melanoma (EMA label). The phase 3 OPTiM registration study showed an overall response rate (ORR) of 26%. Since December 2016, 48 eligible patients started treatment at the Netherlands Cancer Institute. We included 26 patients in this study with a follow up time ≥6 months, reporting Overall Response Rate (ORR), Disease… Expand
Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)
...
1
2
3
4
...

References

SHOWING 1-10 OF 15 REFERENCES
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Improved survival with ipilimumab in patients with metastatic melanoma.
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
  • J. Chesney, I. Puzanov, +15 authors H. Kaufman
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2018
...
1
2
...